Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 19, 2006, Pages 5212-5216

  Jones, Paul D ^a   Tsai, Hsing Ju ^a   Do, Zung N ^a   Morisseau, Christophe ^a   Hammock, Bruce D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Enzyme inhibition; Soluble epoxide hydrolase; Structure activity relationships

Indexed keywords

ENZYME INHIBITOR; EPOXIDE HYDROLASE; EPOXIDE HYDROLASE INHIBITOR; N (1 ACETYLPIPERIDIN 4 YL) N' (ADAMANT 1 YL)UREA; RECOMBINANT ENZYME; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CONFORMATION; CORONAVIRUS; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG SYNTHESIS; IC 50; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL AVAILABILITY; DOGS; ENZYME INHIBITORS; EPOXIDE HYDROLASES; INHIBITORY CONCENTRATION 50; MOLECULAR CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; UREA;

EID: 33747331141     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.07.009     Document Type: Article

References (22)

1. Arand M., Grant D.F., Beetham J.K., Friedberg T., Oesch F., and Hammock B.D. FEBS Lett. 338 (1994) 251
2. Oesch F. Xenobiotica 3 (1973) 305
3. Zeldin D.C., Kobayashi J., Falck J.R., Winder B.S., Hammock B.D., Snapper J.R., and Capdevila J.H. J. Biol. Chem. 268 (1993) 6402
4. Spector A.A., Fang X., Snyder G.D., and Weintraub N.L. Prog. Lipid Res. 43 (2004) 55
5. Yu Z., Xu F., Huse L.M., Morisseau C., Draper A.J., Newman J.W., Parker C., Graham L., Engler M.M., Hammock B.D., Zeldin D.C., and Kroetz D.L. Circ. Res. 87 (2000) 992
6. Imig J.D., Zhao X., Capdevila J.H., Morisseau C., and Hammock B.D. Hypertension 39 (2002) 690
7. Imig J.D., Zhao X., Zaharis C.Z., Olearczyk J.J., Pollock D.M., Newman J.W., Kim I.H., Watanabe T., and Hammock B.D. Hypertension 46 (2005) 975
8. Spiecker M., and Liao J.K. Arch. Biochem. Biophys. 433 (2005) 420
9. Morisseau C., Goodrow M.H., Dowdy D., Zheng J., Greene J.F., Sanborn J.R., and Hammock B.D. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 8849
10. McElroy N.R., Jurs P.C., Morisseau C., and Hammock B.D. J. Med. Chem. 46 (2003) 1066
11. Kim I.H., Morisseau C., Watanabe T., and Hammock B.D. J. Med. Chem. 47 (2004) 2110
12. Kim I.H., Heirtzler F.R., Morisseau C., Nishi K., Tsai H.J., and Hammock B.D. J. Med. Chem. 48 (2005) 3621
13. Schmelzer K.R., Kubala L., Newman J.W., Kim I.H., Eiserich J.P., and Hammock B.D. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 9772
14. Navia M.A., and Chaturvedi P.R. Drug Discovery Today 1 (1996) 179
15. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Adv. Drug Delivery Rev. 46 (2001) 3
16. Veber D.F., Johnson S.R., Cheng H.Y., Smith B.R., Ward K.W., and Kopple K.D. J. Med. Chem. 45 (2002) 2615
17. Sonda S., Kawahara T., Murozono T., Sato N., Asano K., and Haga K. Bioorg. Med. Chem. 11 (2003) 4225
18. Dhaon M.K., Olsen R.K., and Ramasamy K. J. Org. Chem. 47 (1982) 1962
19. Gomez G.A., Morisseau C., Hammock B.D., and Christianson D.W. Biochemistry 43 (2004) 4716
20. Selected soluble epoxide hydrolase inhibitors were prepared at 6 mg/mL in triglycerides. Each dog was dosed orally with three different inhibitors per experiment (dose = 0.3 mg/kg per inhibitor). Plasma samples were collected at 0, 15, 30, 60, 120, 180, 240, 300, 360, 480, and 1440 min, and analyzed by LC/MS/MS (Quattro Premier; Micromass, MA). The pharmacokinetic parameters were calculated with WinNonlin 5.0 (Pharsight, CA).
21. Humphrey W., Dalk A., and Schulten K. J. Mol. Graph. 14.1 (1996) 33
22. Jones P.D., Wolf N.M., Morisseau C., Whetstone P., Hock B., and Hammock B.D. Anal. Biochem. 343 (2005) 66